BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | Apr 22, 2020
Product Development

Animal studies show Sinovac’s COVID-19 vaccine is protective, does not cause ADE

Less than one week after entering the clinic, Sinovac became the first company to report animal data supporting its COVID-19 vaccine candidate. Sinovac Biotech Ltd. (NASDAQ:SVA) has PiCoVacc in a Phase I/II study and expects...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BC Extra | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

Johnson & Johnson (NYSE:JNJ) hired Jim Swanson as EVP and group chief information officer. He was CIO and head of digital transformation, crop science, at Bayer AG (Xetra:BAYN). Swanson replaces Stuart McGuigan, who left in...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
Items per page:
1 - 10 of 506
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 9, 2020
Product Development

China emerging as a leader in COVID-19 vaccines

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...
BioCentury | Apr 22, 2020
Product Development

Animal studies show Sinovac’s COVID-19 vaccine is protective, does not cause ADE

Less than one week after entering the clinic, Sinovac became the first company to report animal data supporting its COVID-19 vaccine candidate. Sinovac Biotech Ltd. (NASDAQ:SVA) has PiCoVacc in a Phase I/II study and expects...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BC Extra | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

Johnson & Johnson (NYSE:JNJ) hired Jim Swanson as EVP and group chief information officer. He was CIO and head of digital transformation, crop science, at Bayer AG (Xetra:BAYN). Swanson replaces Stuart McGuigan, who left in...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
Items per page:
1 - 10 of 506